Glezer M, et al. - CHOICE-2 was a Russian, multicenter, 6-month, open-label, prospective observational study that evaluated the effectiveness of trimetazidine (TMZ) treatment in patients with various durations of angina pectoris. For this investigation, seven hundred forty-one patients with known durations of disease were divided into 4 groups according to stable angina pectoris (AP) duration, ranging from less than 1 year to more than 9 years. Researchers reported that addition of trimetazidine rapidly (within the first 2 weeks) and significantly reduced the frequency of angina attacks and short-acting nitrate use in patients with stable angina, increased walking distance and improved patient well-being, irrespective of angina duration, including patients with recently diagnosed angina.